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Condensation 
In leading to a higher rate of vaginal deliveries and more rapid vaginal delivery, vaginal misoprostol may 
be superior to buccal misoprostol for cervical ripening at term. 
Implications and Contributions/ AJOG at a Glance 
A. Why was this study conducted? 
• Buccal misoprostol is being used more commonly for cervical ripening but has not been 
well studied 
• Retrospective data indicated buccal misoprostol might be non-inferior to vaginal 
misoprostol 
B. What are the key findings? 
• We did not find buccal misoprostol to be non-inferior to vaginal misoprostol 
• Women in the vaginal misoprostol group had higher rates of vaginal delivery, more rapid 
times from induction to deliveries, and fewer cesareans for fetal heart rate abnormalities 
C. What does this study add to what is already known? 
• Vaginal misoprostol may be superior to buccal misoprostol 
• There were no differences in preference for buccal or vaginal misoprostol routes for 
women in the trial. 
Short title 
IMPROVE trial- buccal versus vaginal misoprostol for cervical ripening  
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Abstract 
Background: Cervical ripening is commonly needed for labor induction. Finding an optimal route of 
misoprostol dosing for efficacy, safety, and patient satisfaction is important and not well studied for the 
buccal route. 
Objective: To compare the efficacy and safety of vaginal and buccal misoprostol for women undergoing 
labor induction at term. 
Study Design: The IMPROVE trial was an IRB-approved, triple-masked, placebo-controlled randomized 
non-inferiority trial for women undergoing labor induction at term with a Bishop’s Score ≤ 6. Enrolled 
women received 25 mcg (1st dose), then 50 mcg (subsequent doses) of misoprostol by assigned route 
(vaginal [VM] or buccal [BM]) and a matching placebo tablet by the opposite route. The primary 
outcomes were time to delivery and the rate of cesarean delivery performed urgently for fetal non-
reassurance. A sample size of 300 was planned to test the non-inferiority hypothesis.  
Results: The trial enrolled 319 women, with 300 available for analysis, 152 VM and 148 BM. Groups had 
similar baseline characteristics. We were unable to demonstrate non-inferiority. The time to vaginal 
delivery was lower for the VM group (median [95% confidence interval] in hours: VM: 20.1 [18.2, 22.8] 
vs. BM: 28.1 [24.1, 31.4], Log-rank test p=0.006, pnon-inferiority = 0.663). The rate of cesarean deliveries for 
non-reassuring fetal status was 3.3% for the VM group and 9.5% for the BM group (p=0.033). The rate of 
vaginal delivery in <24 hours was higher in the VM group (58.6% vs. 39.2%, p=0.001).  
Conclusion: We were unable to demonstrate non-inferiority. In leading to a higher rate of vaginal 
deliveries, more rapid vaginal delivery, and fewer cesareans for fetal issues, vaginal misoprostol may be 
superior to buccal misoprostol for cervical ripening at term. 
Trial Registration: clinicaltrials.gov (NCT02408315) 
Key Words: buccal, cervical ripening, labor induction, misoprostol, term pregnancy, vaginal 
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Introduction 
The rate of labor induction has doubled over the last 25 years, with nearly 25% of gravid women 
undergoing labor induction in the United States.1 The goal of induction of labor is to achieve vaginal 
delivery by stimulating uterine contractions, cervical dilation, and active labor. Labor is typically induced 
when the risks of continuing the pregnancy outweigh the risks of delivery or labor induction.2 
Often when labor is induced, the cervix must be “ripened”, a process involving cervical softening, 
thinning, and dilation to help facilitate the successful induction of labor.2 Prostaglandins have been 
effectively utilized for cervical ripening and labor induction for decades as they induce both cervical 
changes and stimulate uterine contractions.3 Misoprostol, a synthetic prostaglandin E1 analogue, has been 
shown to be an effective and safe drug for induction and is the most frequently used induction method.2, 4, 
5
  According to both the World Health Organization and the American College of Obstetricians and 
Gynecologists (ACOG) Practice Bulletin on Induction of Labor, doses of 25 mcg and higher are typically 
administered every 4-6 hours, depending on provider preference.2 
Misoprostol is currently administered in many different ways.6 It can be administered vaginally, 
rectally, orally, buccally, and sublingually.7, 8 While vaginal administration of misoprostol is most 
common, recent trends in practice have shifted toward more buccal use of this drug. A recent survey 
found that midwives indicted a preference toward buccal dosing.9 However, only one published trial 
directly compared buccal to vaginal misoprostol.10 In that trial of 157 women, there were no significant 
differences in any of the outcomes other than higher rates of tachysystole in the buccal group. However, 
that trial utilized higher doses of misoprostol (up to 100mcg) than are typically used clinically.2 A recent 
retrospective cohort study of 207 women also found that time to delivery may be similar for the two 
routes of administration.11 Clinical experience at our center and these retrospective observations led to a 
hypothesis that the two routes were clinically equivalent. Given that if buccal was not inferior clinically to 
vaginal dosing and that patients may prefer avoiding additional vaginal examinations to place medication, 
a non-inferiority trial was warranted. 
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The primary objective of the Induction with MisoPRostol: Oral mucosa versus Vaginal 
Epithelium (IMPROVE) study was to compare the efficacy and safety of vaginal and buccal misoprostol 
for women undergoing labor induction at greater than or equal to 37 completed weeks gestation with a 
live fetus.  
Materials and Methods 
The IMPROVE trial was a triple-blinded, placebo controlled study conducted from August 2015 
through October 2017 at two hospitals in Indianapolis, IN served by the Indiana University (IU) School of 
Medicine Department of OB/GYN and the physicians and certified nurse midwives of the HealthNet 
medical group. The first participant was enrolled 10/4/2015 and the final participant was enrolled 
10/3/2017. This study was a triple masked, randomized controlled trial for inpatient women on labor and 
delivery receiving misoprostol for cervical ripening during labor induction.   Funding for the study was 
provided by the IU Department of OB/GYN. The trial was conducted under a U.S. Food and Drug 
Administration Investigational New Drug application (IND#: 122727), was approved by the IU IRB, and 
was registered on clinicaltrials.gov (NCT 02408315). A Data & Safety Monitoring Board reviewed 
blinded results for efficacy and safety after recruitment of 50 women, 150 women, and at trial completion. 
The full details of the Methods of the study are presented in Supplementary Material. 
Participants 
Women who presented to the labor and delivery unit for delivery who required cervical ripening 
were eligible for the trial. Women ≥14 years of age undergoing either a medically indicated induction of 
labor at a gestational age beyond 37 0/7 weeks or an elective induction of labor after 39 weeks with a 
singleton pregnancy in the cephalic presentation, and a modified Bishop score ≤ 6 (commonly used as a 
cutoff for the need for cervical ripening) were eligible for enrollment. Women were excluded if they had a 
known prior uterine scar, untreated cervical infection, known major fetal congenital anomaly, or evidence 
of fetal compromise (Category 2 or 3 fetal tracing) before the start of the induction. All women underwent 
the informed consent. 
Study drugs and preparation 
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Misoprostol tablets (100 micrograms) were obtained from the manufacturer (Novel Laboratories, 
Somerset, NJ).  Identical placebo tablets were obtained from University of Iowa Pharmaceuticals. Tablets 
were divided in half or quarters (25 or 50 microgram doses) by the Investigational Pharmacies and 
packaged in identical foil packets labeled either “Vaginal” or “Buccal”. 
Randomization and allocation concealment 
Computer-generated, stratified randomization with blocks of size 10 was used for each hospital 
with 1:1 assignment to treatment group.  After informed consent was obtained by the study team, the 
appropriate Investigational Pharmacy was notified. The pharmacist on duty obtained the next sequentially 
numbered study drug packet and sent it to labor and delivery.  Other than the investigational pharmacist, 
who did not have direct subject contact, no investigators, providers or patients had knowledge of 
randomization assignment. 
Study procedures  
After obtaining informed consent and obtaining study drugs in air-tight foil packs from the 
pharmacy, the tablet marked “Buccal” was placed between the teeth and mucous membrane of the cheek 
and the tablet marked “Vaginal” was placed by the clinical care provider high into the posterior vaginal 
fornix. The initial dose of misoprostol used in this protocol was 25 mcg. Subsequent doses, if utilized, 
were 50 mcg in accordance with the ACOG Practice Bulletin.2 Throughout the cervical ripening and 
induction process, continuous external electronic fetal monitoring was utilized as per standard hospital 
practice.   
Cervical examinations were performed approximately every four hours, prior to buccal and 
vaginal administration of the next dose. An additional dose (50 mcg) of study drug was given if clinically 
indicated. Study participation and drug placement continued until there was either: 1) adequate response 
and cervical ripening was no longer needed, 2) signs of tachysystole, non-reassuring fetal heart tracing, or 
other adverse event that would make the provider stop the misoprostol, or 3) 24 hours of study drug given 
(maximum of 7 doses). After cervical ripening was complete or the participant was taken off of the study, 
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there were no limitations placed on the clinical care. At least 30 days after delivery, data was abstracted 
from the medical record to capture all relevant maternal and newborn outcomes and complications. 
Outcomes assessment 
The primary efficacy outcome was the time to delivery, defined as the time from placement of the 
first dose of study drug to the time of delivery. The primary safety outcome was the rate of cesarean 
delivery performed urgently for fetal non-reassurance as the primary indication, however the study was 
not powered for this outcome. Secondary efficacy and safety outcomes included typical outcomes during 
labor and delivery, such as labor characteristics and other medications used (for full list, see 
Supplementary Material). The IMPROVE trial also assessed participant satisfaction with a modified tool 
from Nassar.12  
At least 30 days after delivery, the medical records of the participant and her newborn were 
reviewed and data abstracted from the medical record to capture all relevant maternal and newborn 
outcomes and complications.  
Statistical analysis and sample size calculations 
The study was planned as a non-inferiority trial to assess the primary outcome of time to delivery. 
This was based on our retrospective study finding similar times to delivery.11 Our data found that the 
median time to delivery with both buccal and vaginal misoprostol was about 18 hours. If the buccal route 
was non-inferior, we hypothesized that participant discomfort would be less with buccal as additional 
vaginal examinations might be avoided. A sample size of 300 women with 260 expected vaginal 
deliveries11 was estimated to have 80% power to test a null hypothesis that the hazard ratio (HR) of BM 
relative to VM would be ≤ 0.74 vs alternative hypothesis that the HR > 0.74 with type I error set at 0.05.  
This non-inferiority margin was derived from retrospective data on time to delivery by both routes, which 
equated to approximately a 4.5 hour difference in median time to delivery.  For all other outcomes, the 
two-sided superiority p-values are provided.  
Participant and delivery characteristics were compared between treatment groups using 
appropriate tests (T-test, Wilcoxon rank sum test, Chi-square test, or Fisher’s exact test).  For the primary 
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outcome of time to delivery, median time to delivery and associated 95% confidence intervals (CI) were 
estimated by Kaplan-Meier method for the overall cohort and by route of delivery.  The time to vaginal 
delivery for women who required cesarean delivery was censored at the time of cesarean.  Cox 
proportional hazards regression was used to estimate the HR for BM relative to VM for delivering 
vaginally and associated 95% CI.  A p-value < .05 provides evidence to reject inferiority and conclude the 
buccal route of dosing is non-inferior to the vaginal route.  In secondary analyses, the HR and associated 
95% CI for route of misoprostol was also estimated from the Cox proportional hazards regression, 
adjusting for covariates known to be associated with time to delivery.  All analyses were based on 
assigned group and completed with SAS software version 9.4 (SAS Institute, Inc. Cary, NC). 
Results 
Participant Characteristics 
Of 329 women consented for the trial (Figure 1), ten were excluded before randomization, either 
because they withdrew their consent after signing or were found to not meet inclusion criteria on a 
secondary chart review in preparation for randomization. Thirteen randomized women (4%) did not 
receive the allocated intervention, most (8) because they developed an exclusion criteria before study 
drug placement, typically either fetal tracing abnormalities or cervical dilation change. Six women (2%) 
randomized and initially dosed were administratively withdrawn from analysis after later discovery of 
documentation or consent issues making them ineligible. This left 300 women (94% of those randomized) 
eligible for analysis, of whom 152 received VM and 148 received BM (Figure 1).   
Demographic characteristics by treatment group are provided in Table 1.  Overall, randomization 
achieved balanced groups.  The most common indications for induction were late-term pregnancy (27%), 
hypertensive disorder (21%), and diabetes mellitus (10%).  Hispanic women comprised 29% of the cohort 
and 31% of women were African-American.  Forty-one percent of the women were nulliparous. The 
mean gestational age of both groups was just over 39 weeks. 242 women (80.7%) had a successful 
induction and delivered vaginally (Table 2). One woman in the trial was sent home after receiving a 
course of study drug, returned at a later date, and delivered vaginally; this participant was censored at 
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time of discharge for the primary outcome of time to delivery but was included in all other analyses.  
Reasons for stopping misoprostol use were typical for cervical ripening and included sufficient cervical 
ripening (34%), safety concerns- most commonly tachysystole or fetal heart tracing abnormalities (27%), 
active labor (6%), or multiple reasons together (23%) (Table 2). 
Primary outcomes 
The primary outcome of time to delivery from receipt of first dose of misoprostol was 
significantly longer for women receiving BM rather than VM (median [95% CI]; BM: 28.1 [24.1 to 31.4] 
hrs vs. VM: 20.1 [18.2 to 22.8] hrs, p = .006) (Table 2, Figure 2 Top Panel).  Based on the Cox 
proportional hazards model, the BM vs. VM HR for vaginal delivery is 0.70 [0.54 to 0.90], thus our null 
hypothesis that the HR ≤ 0.74 is not rejected (Pnon-inferiority = 0.663) and we cannot conclude BM is non-
inferior to VM.   
For the primary safety outcome, there was higher rate of urgent cesarean delivery for fetal non-
reassurance in women receiving BM (n=14, 9.5%) vs. VM (n=5, 3.3%), p=0.033 (Table 2, Table S1).  
Covariates known to be associated with time to delivery were included in a full Cox proportional 
hazards model to estimate the adjusted HR for BM vs. VM for time to delivery (Table 3).  In the adjusted 
model, the BM vs. VM adjusted HR is 0.59, [0.45 to 0.77], p<0.0001 (Table 3). Thus, VM was found to 
be superior after adjustment for covariates. Although the assumption of proportional hazards was not 
rejected for this full model (P=0.062), the two-way interaction between parity and log of time to delivery 
and oxytocin and log of time delivery were both significant at the 0.05 level.  Thus, we ran additional 
models to examine these important covariates (Supplemental Material). Multiparous women had a larger 
difference in median time to delivery between treatment groups compared to nulliparous women (Tables 
S3, S4, and Figure 2 Bottom Panel).     
Secondary outcomes  
The rate of vaginal delivery within 24 hours from start of induction was significantly higher in the 
VM group (58.6% vs. 39.2%, RR 1.49 [1.17 to 1.90], P=0.001).  The number of doses of misoprostol 
required to achieve active labor was significantly less in the VM group (median [range]: 2 [1-5] vs. 3 [1-
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7], P<0.001).  The reason for stopping misoprostol was cited as sufficient cervical ripening more 
frequently for women in the VM group (39.5% vs. 29.1%, p=0.006). The maximum dose of oxytocin 
used during labor for women in the BM group was higher than for the VM group (6 mu/min vs. 4 
mu/min, p=0.001). The overall rates of cesarean delivery were similar in the two groups (VM 15.8%, BM 
22.3%, p=0.15). There were no other statistically significant differences in treatment groups on delivery 
characteristics (Table 2) or in maternal or fetal serious adverse events (Table S1). 
Participant preferences 
 There were no differences in participant satisfaction responses obtained the first or second day 
after delivery regarding their experience with induction of labor, expectations on pain, comfort regarding 
route of misoprostol, route they liked better, or preference of route in future IOL (Table S5).  When asked 
which way of giving the medication was more comfortable, 43% responded they were the same, 39% said 
in the cheek, and 13% said in the vagina. When asked which dosing location would they prefer for a 
future induction if both medication routes were equivalent, 41.7% [36.1% to 47.3%] preferred “in my 
cheek”, 31.3% [26.1% to 36.6%] preferred “in my vagina”, and 21.7% [17.0% to 26.3%] said they were 
not sure.  
Structured Discussion/Comment 
1. Principal Findings 
In the IMPROVE trial, women receiving vaginal misoprostol, compared to buccal misoprostol, 
were more likely to deliver more rapidly, deliver vaginally within 24 hours, and require fewer doses of 
misoprostol to achieve active labor.  The buccal misoprostol group had significantly more cesarean 
deliveries for fetal non-reassurance.  There were no differences in other adverse safety events.   
2. Results in context 
Several systematic reviews have compared alternative routes of misoprostol use to the vaginal 
route.13-15 Most have found similar effectiveness of non-vaginal routes. Buccal dosing of misoprostol 
cannot be assumed to be the same as the more studied sublingual dosing. Analysis of the 
pharmacokinetics of misoprostol given by buccal and sublingual routes clearly demonstrate differences.16 
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The onset of action of oral and sublingual routes are similarly fast (8-11 minutes) compared to vaginal 
route (20 minutes). However, most of the pharmacokinetic studies on misoprostol use high doses 
(600mcg or more) not typically used for labor induction. The Cochrane Review comparing buccal to 
vaginal dosing of misoprostol identified only one trial of buccal vs. vaginal misoprostol. However, it 
utilized different doses of misoprostol for each route of administration, making direct comparison 
impossible.14 The authors concluded that larger efficacy and safety trials were required to evaluate the 
buccal route. This has been accomplished in our trial.  
Our rates of serious adverse events were low and were mostly due to prolonged hospitalization. 
Rates of tachysystole requiring therapeutic intervention were 14% in the vaginal group and 12% in the 
buccal group- similar to rates found in some other trials.12, 17  This is in contrast to the trial by Carlan et al. 
which demonstrated higher rates of misoprostol-induced hyperstimulation needing treatment in the buccal 
group (26%) than in the vaginal group (18%). However, that study used up to 300 mcg of buccal 
misoprostol but only 50 mcg vaginally.10  
3. Clinical implications  
As labor inductions are common, finding optimal methods to accomplish vaginal delivery is 
important. We have demonstrated that at typically used doses, vaginal misoprostol leads to more rapid 
deliveries and has fewer urgent cesarean deliveries for fetal distress than buccal dosing. Given the recent 
findings of the ARRIVE trial,18 it is possible that the number of labor inductions will increase, further 
adding to the importance of optimizing this procedure.  
Our subgroup analysis found that for multiparous women, vaginal dosing was superior to buccal 
dosing.  This finding was true even after adjusting for other covariates such as the Bishop Score at trial 
entry. This may be due to biochemical differences in the cervices of nulliparous and multiparous women. 
Further investigation is warranted as subgroup analyses are exploratory, but it is possible that residual 
uterine and cervical factors from prior deliveries may make multiparous women more responsive to 
vaginal misoprostol. As nulliparous women frequently need cervical ripening, we plan to further explore 
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the potential equivalence of the dosing routes in this group. A trial powered for nulliparous women is 
warranted. 
While we hypothesized that women undergoing labor induction would strongly prefer the 
medication by a non-vaginal route, we found similar rates of satisfaction with labor induction and dosing 
regimen preferences between groups. This is in contrast to previous, but non-blinded studies that have 
found participants prefer sublingual dosing.12, 19  By administering study drug both buccally and vaginally 
in a blinded fashion, preferences were not different. Interestingly, the rate of women preferring to have 
the medication in the cheek for a future induction was not much higher than those preferring the vagina 
(42% vs. 31%, respectively). However, as the women were already anticipating cervical examinations, 
perhaps that led to a large number preferring vaginal dosing. In practice, however, when practitioners are 
not blinded to study drug as in our study, they may choose to skip some cervix examinations during 
cervical ripening with buccal dosing. This may have also influenced the route choice responses from 
participants. We did not specifically ask about the taste of the tablets, which also may have played a role 
in the responses. 
4. Research Implications 
We are currently exploring potential pharmacokinetic differences in the two dosing routes and the 
role they may play in outcomes from misoprostol. Further exploration of the differences in response of 
nulliparous and multiparous women is also warranted as providers attempt to individualize labor 
induction methods. A systematic comparison of available dosing and routes of misoprostol for labor 
induction is warranted that would include buccal dosing. 
5. Strengths and Limitations 
The major strength of our trial is that it had blinding of participants, providers, and study 
personnel/outcomes assessors (triple blinding), as well as during data analysis, which reduces bias as 
compared to prior trials. To our knowledge, this is one of only a few trials utilizing buccal misoprostol in 
the same dose as vaginal misoprostol for cervical ripening and labor induction at term for women with a 
live fetus. As many of our providers are uncomfortable placing vaginal drug in women with ruptured 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14 
 
membranes, we enrolled only one woman with ruptured membranes. Thus, our findings are essentially 
limited to women with intact membranes.  Our study was stratified by site and differences between the 
populations at each site were accounted for in the analysis.  But there could have been other differences in 
the two populations unaccounted for. Our findings of potential equivalence of the routes in nulliparous 
women is limited by this being a subgroup analysis not in the original power calculation. 
6. Conclusions 
In conclusion, we were unable to confirm non-inferiority of buccal vs. vaginal misoprostol. In 
fact, we found that vaginal misoprostol may be superior to buccal misoprostol for cervical ripening at 
term.  However, an RCT specifically powered to detect a clinically meaningful difference for which to 
conclude superiority of vaginal misoprostol to buccal is still required.  Vaginal dosing appears to lead to 
more rapid delivery and fewer cesareans for fetal distress.  
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Figure Legends 
Figure 1. Consort diagram of participant flow through IMPROVE trial 
Figure 2. Top Panel:  Kaplan-Meier curves for time to delivery from start of induction in hours for all 
women in IMPROVE trial stratified by route of misoprostol.  Bottom Panel: Kaplan-Meier curves for 
time to delivery for participants stratified by nulliparous (yes or no) and route of misoprostol. Women 
delivered by cesarean are censored at the time of that delivery. Numbers below the graphs are the number 
of women in each group still pregnant at that time point. 
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Table 1: Demographic characteristics of women in the IMPROVE at study entry 1 
Characteristic VM group 
 (n= 152) 
BM group 
(n= 148) 
Age – yr. Mean ±SD     28.2±6.4 27.6±6.4 
Site – no. (%)   
Eskenazi 86 (56.6) 83 (56.1) 
Methodist 66 (43.4) 65 (43.9) 
Nulliparous women – no. (%) 59 (38.8) 65 (43.9) 
Race/Ethnicity – no. (%)   
White 74 (48.7) 66 (44.6) 
African American 45 (29.6) 49 (33.1) 
Other 33 (21.7) 33 (22.3) 
Ethnicity – no. (%)   
Hispanic/ Latino 42 (27.6) 44 (29.7) 
Non-Hispanic /Non-Latino 109 (71.7) 99 (66.9) 
Prefer not to Answer 1 (0.7) 5 (3.4) 
BMI  kg/m2 Mean ±SD     35.7±7.2 35.1±7.3 
BMI category – no. (%)   
<18 0 1 (0.7) 
18-25 7 (4.6) 12 (8.1) 
25-30 22 (14.5) 22 (14.9) 
30-40 87 (57.2) 77 (52.0) 
>40 36 (23.7) 36 (24.3) 
Gestational age at trial entry weeks Mean ±SD 39.6 (1.3) 39.5(1.3) 
Indication for induction – no. (%)   
Fetal Indications 10 (6.6) 17 (11.5) 
Hypertensive disorder 33 (21.7) 31 (21.0) 
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Diabetes mellitus 10 (6.6) 20 (13.5) 
Late-term pregnancy (≥ 41+0 weeks) 44 (29.0) 36 (24.3) 
Elective 21 (13.8) 13 (8.8) 
Multiple reasons 13 (8.6) 13 (8.8) 
Other 21 (13.8) 18 (12.2) 
Epidural – no. (%) 127 (83.6) 122 (82.4) 
Cervical dilatation– no. (%)   
<1 cm 31 (20.7) 37 (25.2) 
1-2 cm 102 (68) 89 (60.6) 
>2 cm 17 (11.3) 21 (14.3) 
Cervical dilatation cm Mean ±SD 1.3±0.9 1.3±0.9 
Effacement of Cervix – no. (%)   
0-30% or > 4cm length 82 (54.7) 82 (55.8) 
40-50% or 3-4 cm length 62 (41.3) 52 (35.4) 
60-70% or 1-2 cm length 5 (3.3)         10 (6.8) 
Effacement of cervix measure %. Mean ±SD     31.7±20.8 31.8±22.8 
Fetal station (cm) – no. (%)   
-3 106 (72.1) 106 (72.6) 
-2 34 (23.1) 36 (24.7) 
-1,0 7 (4.8) 4 (2.7) 
Fetal station cm Mean ±SD     -2.8±0.8 -2.8±0.7 
Bishop score Mean ±SD     2.3±1.7 2.2±1.7  
No statistically significant differences in any baseline characteristics between groups. 2 
  3 
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Table 2: Labor and delivery outcomes of women in IMPROVE study 4 
 
n = 152, 24 
censored 
n = 148, 34 
censored 
P Value* HR [95% CI]* P Valuenon-
inferiority 
Time to delivery (hours)– 
Median [95% CI]  
 
20.1 [18.2, 22.8] 
 
28.1 [24.1, 31.4] 
 
0.006 
 
0.70 [0.54, 0.90] 
 
0.663 
 
VM group 
 (n= 152) 
BM group  
(n= 148) 
P Value†  
  
Cesarean for Fetal non-
reassurance– no. (%) 
5(3.3) 14 (9.5) 0.033   
Vaginal delivery in less than 
24 hours– no. (%) 
89 (58.6) 58 (39.2) 0.001   
Reason for stopping 
misoprostol – no. (%) 
  0.006‡   
Onset of active labor 7 (4.6) 10 (6.8)    
Sufficient cervical 
ripening 
60 (39.5) 43 (29.1)    
Safety concerns 47 (30.9) 34 (23)    
Multiple reasons 31 (20.4) 38 (25.7)    
Other 7 (4.6) 23 (15.5)    
Route of delivery– no. (%)   0.151   
Vaginal delivery 127** (84.2) 115 (77.7)    
Cesarean delivery 24 (15.8) 33 (22.3)    
Cesarean (indications) – no. 
(%) 
N = 24 N = 33   0.376‡   
Fetal non-reassurance 5 (20.8) 14 (42.4)    
Arrest of dilation 3 (12.5) 4 (12.1)    
Arrest of descent 3 (12.5) 1 (3.0)    
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Multiple reasons 11 (45.8) 11 (33.3)    
Other 2 (8.3) 3 (9.1)    
Chorioamnionitis– no. (%) 7 (4.6) 10 (6.8) 0.420‡   
Postpartum hemorrhage– no. 
(%) 
8 (5.3) 6 (4.0) 0.620‡   
Blood transfusion– no. (%) 1 (0.6) 1 (0.7) 0.794‡   
Oxytocin use– no. (%) 100 (65.8) 111 (75) 0.081   
# doses of misoprostol needed 
to get into active labor  
Median (Range) 
2.0 (1.0-5.0) 3.0 (1.0-7.0) <0.001‡   
Maximum units of oxytocin 
administered Median (Range) 
4.0 (0 -36.0) 6.0 (0-30.0) 0.001‡   
† P-Values obtained from T-Test (continuous) or Chi-square test (categorical). ‡ P-values obtained from 5 
Wilcoxon rank sum test (continuous) or Fishers’ exact test (categorical). **One subject was admitted into the study, 6 
got discharged and then returned two weeks later to have a vaginal delivery.  Delivery characteristics (except for 7 
route of delivery) are included for this person as they were censored for time to delivery.*P-value from Log-rank 8 
tests, profile likelihood confidence intervals reported for 95% CI of HR.  9 
P-value for non-inferiority hypothesis based on Cox proportional hazards model (H0:  HR ≤ 0.74 vs. HA:  HR > .74), 10 
p-value < .05 provides evidence to reject inferiority and conclude BM is non-inferior to VM. 11 
 12 
 13 
  14 
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Table 3: Multiple Cox proportional hazards regression model for time to delivery (oxytocin 15 
included as baseline covariate). 16 
(N = 300, 242 vaginal deliveries, Model AIC = 2190.2). 17 
Covariate Estimate SE P Value HR [95% CI]† P Valuenon-
inferiority 
Dose route (BM vs. VM) -0.530 0.137 0.0001 0.59 [0.45, 0.77] 0.952 
Site (Eskenazi vs. Methodist) 0.605 0.149 <0.0001 1.83 [1.37, 2.46]  
Maternal age (y)  0.0003 0.012 0.982 1.00 [0.98, 1.02]  
BMI (kg/m2) ‡ -0.010 0.010 0.294 0.99 [0.97, 1.01]  
Nulliparous (no)  1.17 0.171 <0.0001 3.04 [2.19, 4.26]  
Bishop score 0.158 0.038 <0.0001 1.17 [1.09, 1.26]  
Epidural (no vs. yes) 0.622 0.168 0.0002 1.86 [1.33, 2.57]  
Need for oxytocin (no vs. yes) 1.324 0.154 < 0.0001 3.76 [2.77, 5.08]  
†Profile likelihood confidence intervals.  18 
‡ One person missing BMI, imputed with mean of cohort. 19 
Note: HRs <1.00 should be interpreted as that group needing more time to delivery. 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
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Table S1: Adverse events for women in the IMPROVE study 29 
Adverse Event VM group 
 (n= 152) 
BM group 
(n= 148) 
P Value‡ 
Maternal adverse events:    
Any maternal adverse event 34 (22.4) 32 (21.6) 0.876 
Allergic reaction to misoprostol 0 1 (0.7)  
Tachysystole requiring therapeutic intervention 22 (14.5) 18 (12.2)  
Cesarean for distress 5 (3.3) 14 (9.5)  
Other 9 (5.9) 3 (2.0)  
Fetal adverse events:    
Any fetal adverse event 50 (32.9) 51 (34.5) 0.774 
APGAR score at 5 minutes <7 12 (7.9) 8 (5.4)  
Cord gas pH <7.00 2 (1.3) 3 (2.0)  
Unexpected admission to NICU* 20 (13.2) 21 (14.2)  
Other 26 (17.1) 29 (19.6)  
Maternal Serious adverse events:    
Any serious adverse event 9 (5.9) 11 (7.4) 0.461 
Uterine rupture 0 0  
Maternal death 0 0  
Persistent or significant disability/incapacity 0 0  
Inpatient or post-partum hospitalization** 8 (5.3) 11 (7.4)  
Other life threatening event 1 (0.7) 0  
All data are presented as no. (%) 30 
‡ P-Values obtained from Chi-square test. * Unexpected admission to NICU for condition identified after 31 
administration of first dose of study drug. ** Inpatient readmission postpartum or prolongation of existing 32 
hospitalization 33 
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Table S2: Multiple Cox proportional hazards regression model for time to delivery (Oxytocin 35 
included as time-varying covariate, 0 before receipt, 1 at time of receipt). 36 
(N = 300, 242 vaginal deliveries, Model AIC = 2244.1). 37 
 Estimate SE P value HR [95% CI]† P valuenon-
inferiority 
Dose route (buccal vs. vaginal) -0.568 0.137 <0.0001 0.57 [0.43, 0.74] 0.975 
Site (Eskenazi vs. Methodist) 0.347 0.147 0.018 1.41 [1.37, 2.46]  
Maternal age (y)  -0.0002 0.012 0.988 1.00 [0.98, 1.02]  
BMI (kg/m2) ‡ -0.019 0.010 0.055 0.98 [0.96, 1.00]  
Nulliparous (no)  1.113 0.169 <0.0001 3.04 [2.19, 4.26]  
Bishop score 0.146 0.040 0.0002 1.16 [1.07, 1.25]  
Epidural (no vs. yes) 0.619 0.169 0.0002 1.86 [1.32, 2.56]  
1st dose of oxytocin received (yes vs. no) 0.521 0.156 0.0008 1.68 [1.24, 2.29]  
†Profile likelihood confidence intervals.  38 
‡ One person missing BMI, imputed with mean of cohort. 39 
P-value for non-inferiority hypothesis based on Cox proportional hazards model (H0:  HR ≤ 0.74 vs. HA:  HR > .74), 40 
p-value < .05 provides evidence to reject inferiority and conclude BM is non-inferior to VM. 41 
 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
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Table S3:  Time to delivery (hours) by Parity 52 
 
Nulliparous Women 
(N = 124) 
 
 
VM group BM group  
 
n = 59, 18 censored n = 65, 24 censored 
 
P Value† 
Time to delivery (hours)– 
Median [95% CI]  
 
33.4 [27.5, 37.7] 
 
32.7 [28.0, 39.7] 
 
0.912 
 
   
 
Multiparous Women 
(N = 176) 
 
 
VM group BM group  
 
n = 93, 6 censored n = 83, 10 censored 
 
P Value† 
Time to delivery (hours)– 
Median [95% CI] 
 
16.7 [15.0, 18.2] 
 
23.4 [20.3, 28.2] 
 
<.0001 
 
   
†Estimates obtained from Kaplan-Meier method and results of Log-rank test.   53 
 54 
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Table S4:  Multiple Cox proportional hazards regression models for time to delivery fit separately 56 
by Parity 57 
 58 
Nulliparous (YES) 
(N = 124 women, 82 vaginal deliveries) 
Estimate SE P Value HR [95% CI]† 
Dose route (BM vs. VM) 0.116 0.230 0.613 1.12 [0.72, 1.77] 
Site (Eskenazi vs. Methodist) 0.316 0.259 0.223 1.37 [0.83, 2.31] 
Maternal age (y)  0.023 0.023 0.305 1.02 [0.98, 1.07] 
BMI (kg/m2) ‡ -0.018 0.018 0.309 0.98 [0.95, 1.02] 
Bishop score 0.210 0.073 0.004 1.23 [1.07, 1.42] 
Epidural (no vs. yes) 0.878 0.427 0.040 2.41 [0.98, 5.32] 
Need for oxytocin (no vs. yes) 1.224 0.295 < 0.0001 3.40 [1.87, 5.98] 
Nulliparous (NO) 
(N = 176 women, 160 vaginal deliveries) 
Estimate SE P Value HR [95% CI]† 
Dose route (BM vs. VM) -0.815 0.174 <0.0001 0.44 [0.31, 0.62] 
Site (Eskenazi vs. Methodist) 0.747 0.187 <0.0001 2.11 [1.46, 3.05] 
Maternal age (y)  -0.01 0.015 0.508 0.99 [0.96, 1.02] 
BMI (kg/m2) ‡ -0.012 0.012 0.322 0.99 [0.97, 1.01] 
Bishop score 0.148 0.050 0.003 1.16 [1.05, 1.28] 
Epidural (no vs. yes) 0.603 0.188 0.001 1.83 [1.25, 2.62] 
Need for oxytocin (no vs. yes) 1.323 0.188 < 0.0001 3.75 [2.59, 5.42] 
†Profile likelihood confidence intervals.  59 
‡ One person missing BMI, imputed with mean of cohort. 60 
 61 
 62 
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Table S5: Post-Delivery Satisfaction Questionnaire 64 
Participant Questionnaire  Route of Misoprostol 
 
 
1.  How did you feel about your experience with your   
induction of labor? 
Overall  
(n = 300) 
VM 
(n = 149) 
BM 
(n = 141) 
P value† 
     It was a great experience 156 (52.0) 79 (53.0) 77 (54.6) 0.259 
     It was a terrible experience 23 (7.7) 15 (10.1) 8 (5.7)  
     It was neither great nor terrible 98 (32.7) 51 (34.2) 47 (33.3)  
     I’m not sure 13 (4.3) 4 (2.7) 9 (6.4)  
     Missing  10 (3.3) - -  
2. How painful did you feel that your induction was?   (n = 148)  (n = 142)  
     It was less painful than I expected 89 (29.7) 46 (31.1) 43 (30.3) 0.410 
     It was more painful than I expected 78 (26.0) 35 (23.7) 43 (30.3)  
     It was about what I expected 123 (41.0) 67 (45.3) 56 (39.4)  
     Missing  10 (3.3) - -  
3. Which way of receiving the medication was                                                    
more comfortable? 
  (n = 146)  (n = 138)  
     Getting the tablet in my vagina  39 (13.0) 26 (17.8) 13 (9.4) 0.122 
     Getting the tablet in my cheek  116 (38.7) 57 (39.0) 59 (42.8)  
     They both were the same 129 (43.0) 63 (43.2) 66 (47.8)  
     Missing  16 (5.3) - -  
4. Which method of getting the medication did you like 
better? 
 (n = 146) (n = 139)  
     Getting the tablet in my vagina  74 (24.7) 37 (25.3) 37 (26.6) 0.202 
     Getting the tablet in my cheek 115 (38.3) 53 (36.3) 62 (44.6)  
     No preference 96 (32.0) 56 (38.4) 40 (28.8)  
     Missing  15 (5.0) - -  
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5. If you were to have an induction of labor in the future,   
which one would you prefer? 
 (n = 145) (n = 139)  
     I would rather have the medication in my vagina 94 (31.3) 56 (38.6) 38 (27.3) 0.096 
     I would rather have the medication in my cheek 125 (41.7) 56 (38.6) 69 (49.6)  
     I’m not sure 65 (21.7) 33 (22.8) 32 (23.0)  
     Missing  16 (5.3) - -  
All data are presented as no. (%) 65 
†Chi-square test. 66 
 67 
 68 
 69 
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 Figure 1: IMPROVE Trial CONSORT Flow Diagram 
Total number of women 
consented (n=329) 
Excluded before randomization (n=10) 
♦   Not meeting inclusion criteria on 
second review (n=6) 
♦   Later declined to participate (n=4) 
Analyzed  (n=152) 
 
Administratively withdrawn (n=3) 
 
Allocated to Vaginal dosing (n=158) 
♦ Received allocated intervention (n=155) 
♦ Did not receive allocated intervention (n=3) 
o Not meeting inclusion criteria (n=2) 
o Pharmacy delay, withdrawn (n=1) 
Administratively withdrawn (n= 2) 
Discontinued intervention (n=1) 
• Subject decision to withdraw 
   
Allocated to buccal dosing (n=161) 
♦ Received allocated intervention (n=151) 
♦ Did not receive allocated intervention  (n=10) 
o Not meeting inclusion criteria (n=6) 
o Declined to participate (n=2) 
o Pharmacy delay, withdrawn (n=2) 
Analyzed  (n=148) 
 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=319) 
Enrollment 
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Supplementary Appendix Material 
Full IMPROVE Study Methods Details 
Participants 
Women who presented to one of the two labor and delivery units for delivery who required 
cervical ripening were eligible for the trial. If the provider was considering using misoprostol for cervical 
ripening, the women who met inclusion/exclusion criteria were approached by study personnel. Women 
had to be undergoing either a medically indicated induction of labor at a gestational age beyond 37 0/7 
weeks OR an elective induction of labor after 39 completed weeks, be at least 14 years-old, with a 
singleton pregnancy in the cephalic presentation confirmed by either physical examination or ultrasound. 
Women had to have a modified Bishop score ≤ 6 (commonly used as a cutoff for the need for cervical 
ripening). Women were excluded if they had a known prior uterine scar, untreated cervical infection, 
known major fetal congenital anomaly, or evidence of fetal compromise (Category 2 or 3 fetal tracing) 
before the start of the induction. Women were also excluded if they had a known allergy to misoprostol, 
had a planned cesarean delivery, had undergone a prior induction or cervical ripening measures during the 
current pregnancy, or had any other contraindication to labor induction or misoprostol therapy. 
All women underwent the informed consent process in English or Spanish (utilizing either a 
bilingual research team member or a hospital provided interpreter) and provided written informed consent 
prior to study procedures.   
Study drugs and preparation 
Misoprostol tablets (25 and 50 microgram doses) were obtained from the manufacturer (Novel 
Laboratories, Somerset, NJ).  Identical placebo tablets were obtained from University of Iowa 
Pharmaceuticals. Prepared placebo tablets were tested for stability, dissolving characteristics, and other 
characteristics to match the misoprostol tablets as closely as possible. Details on the placebo preparation 
and testing are available upon request. 
The tablets were prepared for distribution by the Investigational Pharmacies of the 2 hospitals in 
the same way. For women who would be randomized to the “vaginal misoprostol” group, the appropriate 
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dose of misoprostol was placed in a foil packet labeled with the study ID number, dosing time, and 
“Vaginal”. An identical placebo pill was prepared in a foil packet labelled in the same way but with the 
words “Buccal” on the label. Similarly, for women randomized to the “buccal misoprostol” group, the 
appropriate dose of misoprostol was placed in a foil packet labelled with the study ID number, dosing 
time, and “Buccal”. An identical placebo pill was prepared in a foil packet labelled in the same way but 
with the words “Vaginal” on the label. Thus, at each study drug dosing time, the participant had one 
packet with a tablet for placement in the vagina and one for placement in the buccal mucosa. 
Randomization and allocation concealment 
Stratified randomization with blocks of size 10 was used to create a separate randomization list 
for each hospital with 1:1 assignment to treatment group by the study statistician.  The computer-
generated randomization list was then provided to the Investigational Pharmacy at both hospitals. The 
Investigational Pharmacy at each hospital prepared packages as described which were to be sent to the 
labor and delivery unit for use. After informed consent was obtained by the study team, the appropriate 
Investigational Pharmacy was notified. The pharmacist on duty obtained the next sequentially numbered 
study drug packet and sent it to labor and delivery.   
Blinding 
This was a triple-blind study. Other than the investigational pharmacists, who did not have direct 
participant interaction, all study investigators and clinical care providers were blinded to the allocation of 
the participants. All clinical care was thus per standard care protocols for all participants. As the 
participant received a tablet placed in the vagina and an identical tablet in the buccal mucosa at the same 
time, participants were unaware of their assignment. The data collectors/outcomes assessors similarly 
collected all data and outcomes unaware of the assignment. All interim safety analyses and reports to the 
Data Safety Monitoring Board were blinded with the groups reported only as “A” and “B”. 
Study procedures  
On presentation for labor induction, clinical evaluation and decision to use misoprostol, the study 
team confirmed that the woman met inclusion/exclusion criteria, obtained informed consent, and recorded 
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baseline data and participant characteristics. The pharmacy was contacted and notified the woman was 
enrolled in the IMPROVE trial.  The pharmacy then sent the “Vaginal” and “Buccal” study drugs to labor 
and delivery for use by the participant. The pill marked “Buccal” was placed between the teeth and 
mucous membrane of the cheek.  A visual aid was used to show the woman the proper placement. They 
were instructed not to disturb the tablet as it dissolves. A small snack with liquid was allowed before each 
buccal dose if the woman desired.  If tablet remained undissolved after 30 minutes, the woman was 
instructed to swallow the remainder of the tablet. The tablet marked “Vaginal” was placed by the clinical 
care provider (physician or midwife) high into the posterior vaginal fornix. The provider placing the drug 
was able to use water-based lubricating jelly to facilitate the examination and decrease participant 
discomfort according to standard local practice. The initial dose of misoprostol used in this protocol was 
25 mcg. Subsequent doses, if utilized, were 50 mcg. This is an accordance with the ACOG Practice 
Bulletin on misoprostol for labor induction.2 
Throughout the cervical ripening and induction process, continuous external electronic fetal 
monitoring was utilized as per standard hospital obstetric practice.  Other forms of monitoring were 
permitted including intrauterine pressure catheters if deemed clinically necessary. 
Subsequent to the initial cervical examination, follow up cervical examinations were performed 
approximately every four hours, prior to buccal and vaginal administration of the next dose. An additional 
dose of study drug was given if sufficient cervical ripening had not been achieved (Bishop Score ≤6), the 
fetal tracing was not currently category 2 or 3, there was no evidence of tachysystole, and there had been 
no adverse reactions to the study drug. These continuation criteria were designed to mimic clinical 
scenarios where additional doses of misoprostol are used. The next dose of study drugs was thus 
administered only if there is not an adequate response (not contracting adequately to achieve active labor) 
to the prior dose per the provider and there was no evidence of fetal nonreassurance. After the initial dose 
of 25mcg, the second and any subsequent doses were 50mcg. Doses above 50mcg were not used for this 
study. Any cervical examinations performed for clinical indications and examinations after 
discontinuation of the drug until the time of delivery were also recorded.   
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If, after at least 4 hours another dose of study drug was deemed to be indicated by the care 
provider, the pharmacy was contacted and the next dose of that participant’s study drugs was sent to labor 
and delivery for use. Study participation and drug placement continued until: 1) there was adequate 
response and cervical ripening was no longer needed, 2) there were signs of tachysystole, non-reassuring 
fetal heart tracing, or other adverse event that would make the provider stop the misoprostol, or 3) 24 
hours of study drug had been given (maximum of 7 doses). At that time, the reason for stopping the study 
(or completion of study procedures) was noted and the clinical provider proceeded with the labor 
induction or augmentation as clinically warranted. After cervical ripening was complete or the participant 
was taken off of the study, there were no limitations placed on the clinical care of the participant and they 
were managed in the usual fashion, allowing augmentation and other procedures deemed needed to 
accomplish delivery. Any interventions subsequent to placement of the first dose of study drug were 
recorded for later analysis. 
Outcomes assessment 
The primary outcomes for the IMPROVE trial involve both efficacy and safety. The primary 
efficacy outcome was the time to delivery, defined as the time from placement of the first dose of study 
drug to the time of delivery. This study was planned to determine if BM could be considered non-inferior 
to VM in time to delivery.  The primary safety outcome was the rate of cesarean delivery performed 
urgently for fetal non-reassurance as the primary indication. Secondary efficacy outcomes included: rate 
of vaginal delivery within 24 hours of the induction beginning, number of doses needed of misoprostol 
for the induction, maximum/total dose of oxytocin utilized for uterine stimulation, and other drugs used 
for cervical ripening or induction of labor after beginning the study drug. The secondary safety outcomes 
assessed were: uterine tachysystole requiring therapeutic intervention, uterine rupture, maternal or fetal 
death, prolonged inpatient hospitalization or new postpartum hospitalization, unexpected NICU 
admission, neonatal cord blood gases (if obtained), Apgar score, birth weight, and rate of 
chorioamnionitis. 
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In an effort to obtain data on women’s preferences for route of receiving misoprostol, the 
IMPROVE trial assessed participant satisfaction with a patient satisfaction tool obtained from the Nassar 
study9 with some customization based on local practices. In short, the women were typically asked to 
complete the survey on the postpartum ward the first or second day after the baby was born. This was 
available in both English and Spanish. They were asked to rate the discomfort they experienced with the 
vaginal and buccal routes and which route they would prefer if both routes were equal in efficacy and 
safety and they needed to be induced again. 
At least 30 days after delivery, the medical records of the participant and the newborn were 
reviewed and data abstracted from the medical record to capture all relevant maternal and newborn 
outcomes and complications.  
Statistical analysis and sample size calculations 
A sample size of 300 women with 260 expected vaginal deliveries (87%, based on prior induction 
data in our hospital) was estimated to have 80% power to test for non-inferiority of time to delivery of 
buccal misoprostol (BM) with a null hypothesis that the hazard ratio of BM relative to VM (HR) ≤ 0.74 
vs alternative hypothesis that the HR > 0.74 with type I error set at 0.05.  This non-inferiority margin was 
derived from retrospective data on time to delivery by both routes, which equated to approximately a 4.5 
hour difference in median time to delivery.  For all other outcomes, the two-sided superiority p-values are 
provided.  
All analyses were performed according to the intention-to-treat principle.  Participant and 
delivery characteristics were compared between treatment groups using appropriate tests (T-test, 
Wilcoxon rank sum test, Chi-square test, or Fisher’s exact test).  Chi-square tests were performed to 
compare participant satisfaction survey questions between treatment groups. For the primary outcome of 
time to delivery, median time to delivery and associated 95% confidence intervals (CI) were estimated by 
Kaplan-Meier method for the overall cohort and by route of delivery (buccal [BM] or vaginal [VM]).  
Women who required cesarean were censored at the time of cesarean and those that did not deliver 
vaginally during the hospital admission were censored at the time of discharge.  Cox proportional hazards 
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regression was used to estimate the HR for BM relative to VM for delivering vaginally and associated 
95% CI.  The test of non-inferiority which is testing the hypothesis H0:  HR ≤ 0.74 vs. HA:  HR > .74 was 
obtained from this model.  A p-value < .05 provides evidence to reject inferiority and conclude the buccal 
route of dosing is non-inferior to the vaginal route.   
In secondary analyses, the HR and associated 95% CI for route of misoprostol was also estimated 
from the Cox proportional hazards regression, adjusting for covariates known to be associated with time 
to delivery.  Additional analysis included checking the proportional hazards assumption by including two-
way interactions between each covariate and the log of time to delivery, checking for heterogeneity in 
treatment effect by examining two-way interactions between treatment effect and each covariate and 
including receipt of oxytocin as a time-varying coefficient in the full proportional hazards model.  These 
results led to a subgroup analysis which was completed for the primary outcome to examine the treatment 
effect by parity (nulliparous vs. multiparous).  Outcomes were evaluated at a 0.05 level of significance.  
All analyses were completed with SAS software version 9.4 (SAS Institute, Inc. Cary, NC) 
 
Results- Full reporting of Cox proportional hazard and adjusted models 
Covariates known to be associated with time to delivery were included in a full Cox proportional 
hazards model to estimate the adjusted HR for BM vs. VM for time to delivery (Table 3).  Covariates 
included are study hospital site, maternal age, BMI at time of admission, parity, Bishop Score at entry, 
use of epidural, and need for oxytocin.  Based on this model, women more likely to delivery vaginally 
were from the Eskenazi study site, were multiparous, had a higher baseline Bishop score, did not receive 
an epidural, and did not require oxytocin. In the adjusted full model, the BM vs. VM adjusted HR is 0.59, 
95% CI, 0.45 to 0.77, p<0.0001; Table 3). Thus, VM was still found to be superior even with adjustment 
for covariates. Thus we still cannot conclude that BM is non-inferior to VM for time to delivery (Pnon-
inferiority = 0.952).  Although the assumption of proportional hazards was not rejected for this full model 
(P=0.062), the two-way interaction between parity and log of time to delivery and oxytocin and log of 
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time delivery were both significant at the .05 level.  Thus we ran additional models to examine these 
important covariates.   
For oxytocin, rather than include an indicator of whether women required oxytocin at any time 
during delivery in the model, we included oxytocin as a time-varying indicator with 0 prior to the first 
dose of oxytocin, and 1 following receipt of the first dose.  Based on this model, the BM vs. VM adjusted 
HR is 0.57, 95% CI, 0.43 to 0.74, which is similar to the primary model with oxytocin as a baseline 
covariate (Supplementary Table S2).  Also, covariate results were similar to the primary model except 
BMI, which trended towards significance (P=0.055).  Based on the Akiake information criterion (AIC), 
with lower values indicating better fit, the first model with oxytocin as a baseline covariate is a better 
model (2190.2 vs. 2244.1, respectively) thus model results with oxytocin as time-varying are included in 
Supplementary Table S2. 
We ran the full model and checked the two-way interaction between each covariate and treatment 
separately.  The only two-way interaction found to be statistically significant was between treatment and 
indicator for nulliparous women (P =0.0007), indicating that the treatment effect for time to delivery 
varies by parity.  Thus a subgroup analysis was conducted for time to delivery by whether or not women 
were nulliparous (Supplementary Table S3, Figure 2 – Bottom Panel).  Among nulliparous women, there 
was not a significant difference in median time to delivery between treatment groups (VM median 33.4 
hours, 95% CI, 27.5 to 37.7 hours vs BM median 32.7 hours, 95% CI, 28.0 to 39.7 hours, P=0.912).  
However, there was a large difference between treatment groups in median time to delivery for 
multiparous women (VM median 16.7 hours, 95% CI, 15.0 to 18.2 hours vs. BM median 23.4 hours, 95% 
CI, 20.3 to 28.2 hours, P<0.0001).  Additionally we ran the full model adjusting for covariates separately 
for nulliparous and multiparous women (Supplementary Table S4).  For nulliparous women, even after 
adjusting for covariates there was not a significant difference in time to delivery between treatment 
groups (BM vs. VM adjusted HR is 1.12, 95% CI, 0.72 to 1.77, P=0.613).  For multiparous women, BM 
vs. VM adjusted HR is 0.44, 95% CI, 0.31 to 0.62, P<0.0001; thus for multiparous women, the vaginal 
route of delivery of misoprostol was clearly superior to the buccal route of delivery. 
